"When there are other alternatives, why risk trying to use the drug that might have elevated risk? I couldn't see Merck saying we're going to market a drug with a safety problem. And if courts determine that Merck was negligent, the company will pay a heavy price in compensation. Vioxx was Merck's fourth top seller, and they knew their decision would be extremely harmful to the company. Kim, Frazier and Gilmartin gathered in the chief executive's conference room at the Whitehouse Station, N.J., campus.